Louann Cable Email & Phone Number

Denver, CO, US

Boulder, Colorado, United States

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases.

Boulder, Colorado

• Focused on oncology drug discovery and early development.
• Execution of primary screening assays to drive chemistry SAR and project advancements for discovery projects.
• Development of cell lines for in vitro and in vivo models to facilitate the discovery of small molecule cancer therapies.
• Responsible for the management, design, and execution of cell-based assays for target validation.

Boulder, Colorado

Boulder, Colorado

• Provided cell biology support for multiple external alliances to identify small molecule inhibitors for the treatment of cancer.
• Responsible for tech transfer activities to outside collaborators.
• Responsible for the development of immunohistochemistry (IHC) biomarkers that could potentially be used as patient selection markers or confirmation of target inhibition for multiple clinical assets (tumors and bone.
• Analyzed human clinical plasma samples to identify potential predictive biomarkers of response and/or markers of pharmacodynamic effects for multiple oncology programs in Phase 1 development.
• Engaged with external collaborators to generate robust IHC data sets utilizing state of the art image analysis technology to demonstrate on-target activity of pexmetinib in patient bone marrow samples.
• Served as the Translational Medicine Project Team Leader, worked effectively as a member of multi-disciplinary, cross-functional teams to accomplish project goals.

Boulder, Colorado

Boulder, Colorado

Investigated potential mechanisms that contribute to alcohol and tobacco use.

Westminster, Colorado

• Responsible for the isolation of primary rat cell lines for experimental purposes: neonatal rat ventricular myocytes (NRVMs), adult rat ventricular myocytes (ARVMs, rat aortic smooth muscle cells (RASMCs).
• Measured total collagen as a potential biomarker for fibrosis in rat tissues.
• Investigated the effect of endothelin I, II and III on IP-One signaling.

RTP, NC

• Identified and validated commercially available ELISA assays as “fit for purpose” to support multiple clinical studies.
• Responsible for tracking, managing, and analyzing critical human clinical plasma samples.
• Performed studies to identify and validate potential predictive biomarkers of response to GSK diabetes and obesity compounds.
• Prepared written validation reports for assays as needed to support clinical research.

RTP, NC

• Primary lead role in the development and optimization of cell-based assays used for high-throughput screening (HTS).
• Produced cell lines containing clinically relevant EGFR and HER2 mutations found in NSCLC.
• Analyzed activating EGFR mutations found in NSCLC to identify patient subsets that would most likely respond to Tykerb therapy.

RTP, NC

Focused on understanding mechanisms of early processes in carcinogenic transformation with an emphasis on transcriptional regulation and tumor suppressor gene function (investigated the role of BRCA1 in transcription).